ArticleClinical cardiology2023
Mortality across the spectrum of hemoglobin level in patients undergoing surgical coronary revascularization.
Article in Clinical cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review and meta-analysis of differences between men and women in short-term outcomes following coronary artery bypass graft surgery.Scientific reports · 2024Pooled it
- Hemoglobin is associated with cardiotoxicity in melanoma patients without anemia receiving immune checkpoint inhibitor therapy.International journal of cardiology. Heart & vasculature · 2025Article
- Ischemic cardio-cerebrovascular disease and all-cause mortality in Chinese elderly patients: a propensity-score matching study.European journal of medical research · 2024Article
- Mortality across the spectrum of hemoglobin level in patients undergoing surgical coronary revascularization.Clinical cardiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreoperative hemoglobin (Hb) level is a predictor of in-hospital and midterm mortality in patients undergoing coronary artery bypass grafting surgery (CABG). However, the debate about the different hazards across Hb levels and sex differences in outcome occurrence is still on the table.
methodsThis is a registry-based serial cross-sectional study at Tehran Heart Center. Nonanemic patients who underwent CABG with complete follow-up data were included. The Restricted Cubic Splines (RCS) in the Cox model was used to calculate the sex-specific correlation between in-hospital, 6-month, and 1-year mortalities and normal Hb levels using odds ratio for the in-hospital and hazard ratios for 6-month and 1-year mortality, adjusted for all possible confounders.
resultsFrom 2005 to 2016, a total of 13,557 patients were included, of which 134 had in-hospital mortality as our primary outcome. Preoperative Hb levels were significantly lower in the deceased. Moreover, dead patients had significantly higher rates of diabetes and hypertension, while lower ejection fraction. Cut-offs for reference Hb level were higher for males compared with females. The correlation between Hb level and in-hospital mortality was nearly U-shaped. Quantitatively, Hb of ≥15.62 and ≤13.25 g/dL for men and that of ≥14.92 and ≤13.4 g/dL for women tended to be associated with higher in-hospital mortality.
conclusionsThe association between preoperative Hb level and in-hospital mortality differs in men and women and does not follow a linear correlation among nonanemic patients. Both low and high numbers in the Hb level spectrum are at greater risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.